Get the Stockscreener App
11.60
5.36%
0.59
After Hours:
11.60
Regenxbio Inc stock is traded at $11.60, with a volume of 1.19M.
It is up +5.36% in the last 24 hours and down -18.88% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$11.01
Open:
$10.81
24h Volume:
1.19M
Relative Volume:
1.61
Market Cap:
$587.23M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-2.2053
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-27.41%
1M Performance:
-18.88%
6M Performance:
+37.93%
1Y Performance:
+54.26%
1-Day Range:
$10.60
$11.78
1-Week Range:
$9.51
$16.00
52-Week Range:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
11.60 | 557.36M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.44 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
847.72 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.79 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | Goldman | Buy → Neutral |
| Feb-07-25 | Resumed | Raymond James | Outperform |
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Regenxbio (RGNX) Receives Reaffirmed Buy Rating from Chardan Cap - GuruFocus
Regenxbio selloff ‘an overreaction’ to clinical hold, says Leerink - Yahoo Finance
H.C. Wainwright reiterates Buy rating on Regenxbio stock amid clinical holds - Investing.com Nigeria
Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load? - simplywall.st
Baird reiterates Outperform rating on Regenxbio stock despite FDA hold - Investing.com
Regenxbio stock falls as FDA places clinical holds on key programs - Investing.com
FDA places clinical hold on REGENXBIO gene therapies after tumor case By Investing.com - Investing.com South Africa
Regenxbio clinical hold does not change thesis, says Clear Street - TipRanks
RGNX shares pare losses as Wall Street dismisses gene therapy clinical hold spurred selloff as an overreaction - MSN
Nippon Shinyaku : Regulatory Update on RGX-111 and RGX-121 - marketscreener.com
Is REGENXBIO Inc. in a long term uptrend2025 Support & Resistance & Safe Capital Allocation Plans - mfd.ru
FDA puts REGENXBIO gene therapy trials on hold after brain tumour - Yahoo
FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials - NeurologyLive
Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations - NewMediaWire
REGENXBIO Faces FDA Clinical Hold on Gene Therapy RGX-111 - Intellectia AI
Regenxbio MPS Programs Slapped With Clinical Hold On Eve Of FDA Decision - Citeline News & Insights
Gene Therapy Stock Crashes On 'Confusing And Unexpected' News - Investor's Business Daily
RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction - Stocktwits
Stifel reiterates Buy rating on Regenxbio stock amid clinical hold By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Regenxbio stock amid clinical hold - Investing.com
Stifel Maintains Positive Outlook on Regenxbio (RGNX) Despite De - GuruFocus
INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC - GlobeNewswire
Regenxbio shares hit by setback with gene therapies - The Pharma Letter
FDA Clinical Hold Knocks REGENXBIO Stock - Benzinga
Regenxbio wrestling holds on MPS I, II gene therapy trials - BioWorld MedTech
Regenxbio gene therapy trials suspended by FDA over safety worries - BioPharma Dive
Regenxbio (RGNX) Experiences Major Setback with FDA Clinical Hol - GuruFocus
FDA suspends two Regenxbio gene therapy trials after patient developed brain tumor - Endpoints News
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval - BioSpace
Regenxbio Says RGX-111, RGX-121 Placed on Clinical Hold by FDA; Shares Tumble Pre-Bell - marketscreener.com
FDA hits pause on Regenxbio gene therapies after child’s brain tumor; stock slumps - Bez Kabli
US FDA places clinical hold on Regenxbio's rare disease program - Reuters
Regenxbio (RGNX) Maintains Buy Rating Despite FDA Clinical Hold - GuruFocus
Regenxbio Plummets After Brain Tumor Found in Trial Participant - Bloomberg.com
Eli Lilly expands work on gene therapies for hearing - statnews.com
FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling - Fierce Biotech
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? - Stocktwits
US FDA places clinical hold on Regenxbio’s rare disease program - PharmaLive
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $37 - 富途牛牛
REGENXBIO (RGNX) Shares Plummet as FDA Halts Gene Therapy Trials - GuruFocus
FDA Halts RegenXBio MPS Gene Therapy Trials - TipRanks
FDA Pauses Regenxbio's (RGNX) Gene Therapy Trials Due to Safety Concerns - GuruFocus
Regenxbio (RGNX) Stock Plummets Following FDA Clinical Hold - GuruFocus
REGENXBIO Inc Receives FDA Clinical Hold on MPS Programs - TradingView
FDA places clinical hold on REGENXBIO gene therapies after tumor case - Investing.com
REGENXBIO falls after FDA clinical hold (RGNX:NASDAQ) - Seeking Alpha
US FDA places clinical hold on Regenxbio's gene therapy trials - marketscreener.com
REGENXBIO stock tumbles after FDA places clinical holds on gene therapies - Investing.com
FDA Clinical Hold Impacts Regenxbio's (RGNX) Gene Therapy Trials - GuruFocus
Why Is REGENXBIO Stock Falling In Pre-market? - Nasdaq
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs - The AI Journal
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):